The European Commission has been criticized for maintaining a culture of secrecy, which has raised concerns about transparency and accountability within EU institutions. The EU Ombudsman, Emily O’Reilly, has been a vocal advocate for increased openness and has called for new standards to be implemented. Since taking office in 2013, O’Reilly has been responsible for investigating cases of maladministration and ensuring that EU institutions are held accountable for their actions.
One notable instance of O’Reilly’s push for transparency was her criticism of Ursula von der Leyen’s undisclosed text messages with Pfizer’s CEO during the COVID-19 pandemic. O’Reilly has also called for the publication of a secret protocol sent to Mercosur, demanded human rights protections in the EU-Tunisia migration deal, and sought clarity from Frontex on its role in Mediterranean search and rescue operations. Most recently, O’Reilly opened an inquiry into the Commission’s decision to relax environmental standards in the Common Agricultural Policy following protests by European farmers.
In a recent interview with Euronews’s Isabel Silva, O’Reilly discussed her efforts to promote transparency within the EU. The full interview will be published this week, providing insight into O’Reilly’s work as EU Ombudsman and her ongoing efforts to hold EU institutions accountable. Additionally, the European Parliament is set to discuss important issues such as the Capital Markets Union and the new plan to finance Ukraine, highlighting the ongoing efforts to address key issues facing the EU.
In France, a trial involving the far-right National Rally party has begun, with accusations that EU funds were used to pay party employees. This case highlights the importance of ensuring that EU funds are used appropriately and transparently, in line with the principles of accountability and good governance. The trial will serve as a test case for addressing misuse of EU funds and ensuring that political parties are held accountable for their actions.
Finally, the discussion on therapies involving psychedelic drugs becoming legally approved in Europe raises important questions about healthcare policies and regulations in the EU. As new treatments and therapies emerge, policymakers must consider the implications for public health and safety, as well as the need for transparency and accountability in decision-making. By addressing these issues, the EU can work towards promoting a culture of openness and transparency in all aspects of governance and decision-making.
